ABIONYX Pharma Provides Further Details on the Setting up of Its Equity-Linked Financing Facility
29 Maggio 2023 - 8:15PM
Business Wire
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world's only natural recombinant ApoA-I, clarifies fundamental
points about the setting up of its latest equity-linked financing
facility, after receiving questions from its shareholders and the
financial community over the past few days.
IRIS's commitment, the subscriber, is key to understanding
ABIONYX Pharma's decision to use this equity-linked financing
facility tool. Unlike other players offering dilutive tools, IRIS
is an investor based in the European Union, whose practices seemed
to best protect the interests of ABIONYX Pharma and its
shareholders. In particular, IRIS did not sell any shares, nor did
request any guarantee on the assets, nor demand any indemnity in
the event that the Company did not call of new tranches. ABIONYX
Pharma would like to emphasise that the next tranches of this
equity-linked financing facility can only be exercised at its own
initiative.
ABIONYX Pharma triggered this financing to secure the launch of
its biomanufacturing activities, which are the key element of
credibility for any technological breakthrough in biomedicines
worldwide, particularly in the context of upcoming clinical trials
and discussions with major pharma players.
As a listed company which has always taken into account the
interests of all its shareholders, ABIONYX Pharma considers that,
in the current stock market and economic context of high interest
rates, the strengthening of shareholders' equity without pressure
from debt was the most appropriate decision to ensure the Company's
strategic development given the clinical results, particularly in
sepsis.
Finally, ABIONYX Pharma would like to point out that the main
shareholders, Domundi, Cyrille Tupin and Luc Demarre, did not sell
any shares, and have no intention of doing so, given the solid
development outlook of the biotech company as it turns to a
pharma.
Next financial press release :
Cash position and activity update for Q2 2023, August 17,
2023
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230529005136/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Mag 2023 a Mag 2024